Coronavirus: Can Companies Achieve Vaccine Ambition?

J&J Best Placed To Accelerate Timelines

Shanghai/China-Jan.2020: New type coronavirus pneumonia in Wuhan has been spreading into many cities in China. People wearing surgical mask sitting in subway in Shanghai
China on alert: people on Shanghai's subway system wearing face masks to minimise the risk of infection

As the death toll rises in China and new cases emerge in other countries, researchers are aiming to slash development times to generate a vaccine against the 2019-nCoV coronavirus.

The death toll from the 2019-nCoV coronavirus in China has now risen to 106 people, with confirmed infections growing to more than 4,500. Cases have also been confirmed in Japan, Hong Kong, Macau, South Korea, Taiwan, Thailand, the US, Germany and France. Despite this alarming rise in cases, the head of the World Health Organization Tedros Adhanom Ghebreyesus has said he is confident that China can contain the outbreak. It has, for now, stopped short of declaring it an international emergency, but could do so if the virus’s spread is not held back.

Johnson & Johnson’s Janssen division and a parallel effort led by new public-private coalition which have been fastest to respond.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from R&D

  • ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership

     
    • By 

    The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

More from Scrip